October 19, 2017 8:30 PM ET


Company Overview of Druggability Technologies Holdings Limited

Company Overview

Druggability Technologies Holdings Limited, through its subsidiaries, develops and commercializes NanoActive, its proprietary high throughput technology platform. The company also develops nano formulations with improvements and clinically meaningful benefits over original drug formulations. The company was incorporated in 2011 and is based in Dublin, Ireland.



Founded in 2011

Key Executives for Druggability Technologies Holdings Limited

Chief Executive Officer
Compensation as of Fiscal Year 2017.

Druggability Technologies Holdings Limited Key Developments

Druggability Technologies Holdings Ltd Announces Results of Phase I study of DRGT18-2

Druggability Technologies Holdings Ltd. announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®), originally a Pfizer product approved by the FDA. Sirolimus, as developed by Pfizer and approved by the FDA, initially failed to achieve sufficient therapeutic effect in clinical practice due to adverse effects in patients undergoing treatment for prophylaxis of organ rejection receiving renal transplants. Sirolimus has unfavorable PK properties including low bioavailability and high patient variability. These can be major limitations of its therapeutic utility. As an immunosuppressant, organ rejection shows correlation with low Sirolimus blood levels; and toxicity attributed to over-exposure can often lead to discontinuation. The drug shows positive therapeutic effect in mTOR-responsive malignancies, yet it may not be possible to reach the necessary therapeutic exposure safely and reliably with Rapamune®. This lead DRGT to the development and application of the company’s Super-API drug development platform to the Sirolimus drug. Phase 1 study results utilizing the new DRGT18-2 formulations may improve patient outcomes by demonstrating a two-fold improvement in therapeutic bioavailability versus patients receiving Sirolimus in clinical practice. Combined with improved bioavailability there was also a substantial reduction in patient variability over the dosage range tested, 0.5 mg to 40 mg.

Druggability Technologies Holdings Limited Announces Results from Phase I Pain Programs

Druggability Technologies Holdings Ltd. has announced the Phase I clinical results of its DRGT-46 and DRGT-47 programs, new compositions of Celecoxib, a COX-2 selective nonsteroidal anti-inflammatory drug, or NSAID. There are many treatment options for pain. Traditional NSAIDs (e.g.; ibuprofen, naproxen) are nonselective - they inhibit both COX-1 and COX-2. The inhibition of COX-2 accounts for pain relief and anti-inflammatory effects, whilst the inhibition of COX-1 can lead to toxicity and associated side effects (ulcers, prolonged bleeding time, kidney problems). Celecoxib is the only COX-2 inhibitor on the market. It is used to treat pain and inflammation, however its use in pain management is limited by a long "kick in" time as a pain killer (50 mins - 1.5 hours) even at the highest (400mg) dose.DRGT-46 (200 mg) and DRGT-47 (100 mg), novel Super-API compositions were developed by DRGT as new fast and flexible treatment options for acute and chronic pain. In a Phase I clinical study DRGT-46 and DRGT-47 showed very rapid absorption and the opportunity for immediate pain relief. The published effective concentration for onset of action (Ceff =250 ng/ml) was reached within 12 minutes at both doses (100 and 200 mg); under both fasted and fed (high fat) conditions.

DRGT Announces Dr. Philip Kantoff as Senior Clinical Advisor

DRGT has announced that Dr. Philip Kantoff has joined the leadership as Senior Clinical Advisor to accelerate the progress of its ambitious oncology drug development program. Dr. Kantoff is the Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York. He also served as Director of The Lank Center for Genitourinary Oncology, Chief of the Division of Solid Tumor Oncology, Vice Chair of the Department of Medical Oncology, and Chair of the Executive Committee on Clinical Research at the Dana-Farber Cancer Institute. He is a Professor Emeritus of Medicine at Harvard Medical School, the Chairman of the Global Treatment Science Network of the Prostate Cancer Foundation, and member of numerous professional societies and editorial boards. Dr. Kantoff published more than 350 research articles on a variety of topics, written nearly 100 reviews and monographs on cancer and has edited numerous books, including Prostate Cancer, A Multi-Disciplinary Guide published by Blackwell, and Prostate Cancer: Principles and Practice, a definitive text on prostate cancer.

Similar Private Companies By Industry

Company Name Region
Alexo Therapeutics Ltd Europe
Algae Health Ltd. Europe
Alimentary Health Limited Europe
Altratech Limited Europe
Artugen Therapeutics Limited Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Druggability Technologies Holdings Limited, please visit www.drgtco.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.